This inventor holds 3 USPTO granted patents. Top assignees: Kyushu University, Kyowa Hakko Kirin Co., Limited, Kyowa Kirin Co., Ltd.. Active years: 2013-2020.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
3 out of 455 
2 out of 272 
1 out of 46 
Years Active: 2013-2020
Title: **The Innovations of Shin-ichiro Takayanagi: A Pioneer in Antibody Research**
Introduction
Shin-ichiro Takayanagi, based in Tokyo, Japan, is a distinguished inventor known for his significant contributions to the field of antibody research. With a total of three patents to his name, Takayanagi's work focuses primarily on the development of therapeutic agents that have the potential to transform medical treatments.
Latest Patents
Among his latest innovations is the **Anti-TIM-3 antibody**, which represents a breakthrough in therapeutic applications. This invention discloses an anti-human TIM-3 antibody that exhibits high antibody-dependent cellular cytotoxicity (ADCC) activity. Takayanagi's patent describes a method for screening monoclonal antibodies that bind to the extracellular region of TIM-3 or its three-dimensional structure. The patent encompasses the creation of a hybridoma that produces the antibody, the DNA that encodes it, and methods for producing the antibody or its fragments using the hybridoma or a transformed cell line. Moreover, it includes the therapeutic and diagnostic applications of this antibody as an active ingredient, showcasing the potential for significant advancements in cancer treatment.
Career Highlights
Shin-ichiro Takayanagi has been involved with prestigious institutions and companies throughout his career, including the National University Corporation Kyushu University and Kyowa Hakko Kirin Co., Limited. His work in these organizations has facilitated advancements in antibody research, contributing to the development of innovative therapeutic solutions.
Collaborations
Throughout his professional journey, Takayanagi has collaborated with notable peers in the industry, such as Hitomi Tomura and Tomonori Tawara. These collaborations have further enriched his research and have led to significant findings in the realm of immunotherapy.
Conclusion
In summary, Shin-ichiro Takayanagi's innovative work in developing the Anti-TIM-3 antibody exemplifies his dedication to advancing medical science. Through his patents and collaborations, he continues to influence the field of antibody research, promising new avenues for treatment and diagnosis in medicine. His contributions represent the essence of innovation in the fight against diseases, particularly in oncology.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile